1. |
Gonadotropin-releasing hormone antagonists reviewed |
|
Inpharma Weekly,
Volume &NA;,
Issue 1316,
2001,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
2. |
Human therapeutic cloning: potential for transplant therapies |
|
Inpharma Weekly,
Volume &NA;,
Issue 1316,
2001,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
3. |
Guidelines for the treatment of ADHD |
|
Inpharma Weekly,
Volume &NA;,
Issue 1316,
2001,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
4. |
Juvenile RA still a challenge to treat |
|
Inpharma Weekly,
Volume &NA;,
Issue 1316,
2001,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
5. |
Amorolfine plus terbinafinevsterbinafine alone for onychomycosis |
|
Inpharma Weekly,
Volume &NA;,
Issue 1316,
2001,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
6. |
Atazanavir attains anti-HIV effects without altering lipid levels |
|
Inpharma Weekly,
Volume &NA;,
Issue 1316,
2001,
Page 7-8
Sushma Soni,
Preview
|
|
摘要:
48-week data on atazanavir presented at the 8th European Conference on Clinical Aspects and Treatment of HIV-Infection [Athens, Greece; October 2001] show that this potent azapeptide inhibitor of HIV-1 protease has efficacy that is at least comparable to other protease inhibitors, but does not produce any significant alteration of lipid levels. Protease inhibitors have been implicated in the development of elevated cholesterol and/or triglycerides, which is of concern due to the potential for subsequent development of cardiovascular disorders or pancreatitis. This issue has become particularly important as the survival of patients with HIV infection improves as a result of advances in antiretroviral therapy, raising awareness of the longer-term effects of such therapy.
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
7. |
Azimilide 100 or 125 mg/day delays recurrence of atrial fibrillation |
|
Inpharma Weekly,
Volume &NA;,
Issue 1316,
2001,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
8. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1316,
2001,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
9. |
Nicorandil reduces risk of major coronary events in patients with angina |
|
Inpharma Weekly,
Volume &NA;,
Issue 1316,
2001,
Page 11-12
Larry Prescott,
Preview
|
|
摘要:
Nicorandil, a potassium channel agonist known to be effective in patients with chronic stable angina pectoris, has now been shown to have additional cardioprotective qualities. In the IONA*study, presented at the Scientific Sessions of the American Heart Association [Anaheim, US; November 2001], nicorandil significantly reduced the incidence of major coronary events and all cardiovascular events in patients with chronic stable angina.'The IONA trial demonstrates that nicorandil improves outcome in patients with chronic stable angina, adding credence to its value in clinical outcome',said Professor Henry Dargie from the University of Glasgow, UK, who presented the data.'This landmark study is the first demonstration in major coronary events by a specific antianginal medication in a trial large enough to address outcomes'.
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
10. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1316,
2001,
Page 12-12
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|